GLP-1 Open Enrollment 2026: Switch Plans or Cash Pay?

Open enrollment is the one annual window when you can change or add health insurance coverage. And for the growing number of Americans using compounded semaglutide or tirzepatide for weight loss, the October–November 2026 enrollment season raises a specific question: is switching to a plan with GLP-1 coverage actually worth it, or is cash-pay compounded medication the smarter financial move?

By Alexandru Vieru | Independently researched | Published September 2026. Insurance and pricing data verified: August 2026.

Quick answer: For Medicare Part D, open enrollment runs October 15. December 7 and is the right moment to add a plan covering Wegovy for cardiovascular patients. For employer and Marketplace plans, enrollment typically runs October–November with new coverage starting January 1. But here's the math most guides skip: if your current plan doesn't cover GLP-1 medication, switching plans rarely pays off. Because the premium increase for plans that do cover Wegovy ($200–$400/month extra) often exceeds the total cost of compounded semaglutide ($99–$199/month) from a vetted telehealth clinic.

For a full breakdown of how each plan type handles GLP-1 reimbursement today, see our Zepbound insurance coverage guide for 2026 and our GLP-1 cost analysis.

What Is Open Enrollment for GLP-1 Coverage?

Open enrollment is the annual period during which you can enroll in, switch, or drop a health insurance plan without needing a qualifying life event. Outside open enrollment, most Americans cannot change their coverage unless they experience a job change, divorce, birth of a child, or another qualifying event that triggers a Special Enrollment Period.

In 2026, three separate open enrollment windows can affect GLP-1 access:

1. Medicare Annual Enrollment Period (AEP): October 15. December 7. Covers Medicare Advantage (Part C) and standalone Prescription Drug Plans (Part D). This is the primary window if you're on Medicare and need Wegovy for cardiovascular reasons.
2. Employer Open Enrollment Period (OEP): Varies by company but most large employers run enrollment in October or November, with coverage starting January 1. This is where most working-age Americans can consider GLP-1 plan upgrades or benefit riders.
3. ACA Marketplace Open Enrollment: November 1. January 15. Covers individual and family plans purchased through the federal or state marketplace. New coverage starts January 1 (or February 1 for late enrollees).

Each window requires different actions and produces a different financial outcome.

Medicare Open Enrollment 2026: What GLP-1 Patients Need to Know

Medicare's approach to GLP-1 coverage is narrow but meaningful. Medicare Part D covers Wegovy (semaglutide injectable) specifically for patients with established cardiovascular disease (CVD) and BMI ≥27. This policy was unlocked by the SELECT trial (NEJM, 2023), which showed Wegovy reduced major cardiovascular events by 20% in patients with obesity and existing CVD. Giving CMS a mechanism to approve it under Part D as a cardiovascular drug, not a weight-loss drug.

What this means during open enrollment for Medicare patients:

• If you have CVD + BMI ≥27: Compare all Part D plans for Wegovy formulary status during the October 15. December 7 window. Use Medicare's Plan Finder at medicare.gov to search by drug name. Plans vary widely on which tier Wegovy sits and whether they require prior authorization.
• If you have obesity but no documented CVD: Part D does not cover Wegovy for weight-loss-only indication. Your options are: find a Medicare Advantage plan that added GLP-1 as an extra benefit (some did in 2025–2026, check plan documents), use the Medicare Bridge Program if eligible, or pay cash for compounded semaglutide or tirzepatide.
• Medicare Advantage vs. Part D: Some Medicare Advantage plans in 2026 extended GLP-1 coverage beyond the CVD requirement as a supplemental wellness benefit. During open enrollment, compare your current plan's formulary against available alternatives.

For Medicare patients eligible for the $50/month co-pay Bridge Program, see our Medicare GLP-1 Bridge Program guide.

⚠️ Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are custom preparations from 503A-licensed compounding pharmacies, legally distinct from brand-name Wegovy and Zepbound. Medicare does not reimburse compounded medications. Consult your prescriber before starting any GLP-1 therapy.

Employer Open Enrollment and GLP-1 in 2026

For most working-age Americans, the employer open enrollment period is the most practical path to GLP-1 coverage. Or the most common source of disappointment. In 2026, large employers have split sharply:

Employers that kept GLP-1 coverage: Many large self-insured companies (typically 500+ employees) maintained Wegovy and Zepbound as covered benefits, usually requiring prior authorization: BMI ≥30, or BMI ≥27 with a qualifying comorbidity (hypertension, prediabetes, type 2 diabetes, dyslipidemia, sleep apnea, PCOS, or established CVD). If your employer falls into this group, the open enrollment move is simply to confirm your PA documentation is in order and submit it as soon as your new plan year begins.

Employers that dropped GLP-1 coverage: A significant subset of mid-size employers quietly dropped GLP-1 medication from formularies in 2025–2026 after sharply higher premium costs. If your employer removed coverage, no plan tier during open enrollment will restore it. You'll need to confirm this in your Summary of Benefits and Coverage before assuming it exists. Public employers follow the same pattern: the State of Indiana dropped GLP-1 coverage for weight loss on January 1, 2026, while Florida's state plans cover it only for members accepted into a capped Weight Management Pilot Program, whose 2026 applications ran November 3 to 17, 2025. Oklahoma HealthChoice excludes weight-loss drugs for 2026, and Tennessee state plans cover them at 25% coinsurance, a 30-day supply at a time.

Standalone GLP-1 benefit riders: A growing category of third-party benefit platforms now offer GLP-1 weight management programs as add-on riders, separate from your medical plan. These often bundle a telehealth prescription service with a structured program. Check your benefits portal for "weight loss medication" or "GLP-1 program" add-ons during open enrollment.

What to examine during open enrollment at your employer:

1. Open the Summary of Benefits and Coverage (SBC) for each plan option.
2. Search the drug formulary for: semaglutide, tirzepatide, Wegovy, Zepbound, Ozempic. (Ozempic's formulary status is a useful signal even though it's approved for diabetes, not weight loss.)
3. Find the prior authorization criteria for each drug listed. Most plans require BMI documentation plus at least one comorbidity plus evidence of dietary intervention.
4. Calculate the true annual cost: (premium increase × 12) + new deductible + expected copay structure.

That final calculation is where the open enrollment math most often turns against plan switching.

The Math: When Open Enrollment Plan Switching Beats Cash Pay

Here's what most GLP-1 insurance articles don't compute for you.

Scenario A: Your existing plan already covers GLP-1 (with prior auth)

If your current plan covers Wegovy or Zepbound with a prior authorization, file the PA at the start of your benefit year. You pay only the formulary copay. Typically $25–$75/month for Tier 3 drugs after you've met your deductible. With a $1,500 deductible you might pay $1,500 + ($50 copay × remaining months). Against brand-name Wegovy at $349/month self-pay through NovoCare (novocare.com) (checked 26 October 2026), this is still a win for insurance. Scenario A: insurance wins clearly.

Scenario B: You need to switch to a higher-tier plan to get GLP-1 coverage

This is the scenario most people actually face. To get GLP-1 coverage, some employees must move from a silver plan ($350/month premium) to a gold plan ($550/month premium). A $200/month increase, or $2,400/year in additional premiums. Compare that to:

• Compounded semaglutide from a vetted clinic: $99–$199/month × 12 = $1,188–$2,388/year all-in (medication, physician consult, monitoring).
• Extra premium cost for the GLP-1 plan: $200/month × 12 = $2,400/year before any deductible on the new plan.

In Scenario B, compounded semaglutide often wins on cost. Especially if the higher-tier plan carries a larger deductible. This is the scenario where cash pay beats plan switching for most patients.

Scenario C: You're on Medicare without CVD

If you don't meet Medicare's CVD requirement, open enrollment won't unlock Wegovy coverage through Part D. A Medicare Advantage plan with extra GLP-1 benefits is possible but varies by location. For most patients in this group, cash-pay compounded semaglutide ($99–$199/month) or tirzepatide ($179–$279/month) from a licensed telehealth clinic is the practical path.

Rule of thumb: If open enrollment would cost more than $150/month extra in premiums to add GLP-1 coverage, compare that to the cheapest verified GLP-1 options before committing to the plan switch.

Open Enrollment Action Checklist for GLP-1 Patients (5 Steps)

Complete these steps before your open enrollment deadline.

• Step 1. Verify your current plan's GLP-1 formulary now. Log into your insurer's portal. Search for Wegovy and Zepbound specifically. If they appear on any tier, request prior authorization documentation from your prescriber immediately. Don't wait for open enrollment.
• Step 2. Calculate the true cost of switching. (Premium increase × 12) + new deductible + expected copay × remaining months. Then compare to $99–$199/month all-in compounded.
• Step 3. Check for standalone GLP-1 benefit riders. Your employer's benefits portal may offer weight management program add-ons that include GLP-1 prescriptions, separate from your medical plan. Some cost $50–$100/month and include a telehealth component.
• Step 4. Medicare patients: use Plan Finder. During October 15. December 7, visit medicare.gov Plan Compare and filter Part D plans by Wegovy coverage. If you have qualifying CVD, this open enrollment window is your best annual opportunity to reduce cost.
• Step 5. If switching doesn't pay, pick a reliable cash-pay clinic now. If the math shows cash pay wins, get started with a vetted telehealth provider before open enrollment closes. You don't need insurance to begin, and there's no enrollment window for cash-pay compounded GLP-1. You can start any time.

Best Cash-Pay GLP-1 Options If You Skip the Plan Switch

If open enrollment math shows that compounded cash pay beats your plan-switching options, compare our partner clinics below. Each box shows the price, plan length and the date we read it; each review covers the clinical oversight and billing terms that matter most for sustained GLP-1 use.

Compounded semaglutide from our partner clinics, in order of our score:

Wellorithm also carries Wegovy, Zepbound, Ozempic and Mounjaro under one intake, which is useful if your insurance comes through mid-year.

For tirzepatide pricing and a full comparison of every clinic we rank, see the compare table or the cheapest GLP-1 guide.

Affiliate disclosure: MyGLP1 Guides may earn a commission if you sign up through a partner's affiliate link, at no extra cost to you. Links to our reviews are not affiliate links. Commission does not influence our scores. See our editorial policy for the full methodology.

Medical disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved medications. They are individually prepared by licensed 503A compounding pharmacies under physician supervision. Consult a licensed healthcare provider to determine whether GLP-1 medication is appropriate for your health situation.

Frequently Asked Questions

Can I switch to cash-pay compounded GLP-1 and then add insurance coverage later? Yes. There is no enrollment window for cash-pay compounded GLP-1. You can start any time through a licensed telehealth clinic. If your employer's open enrollment later unlocks GLP-1 insurance coverage, you can transition to brand-name Wegovy or Zepbound. Clinics like Wellorithm manage both compounded and brand-name prescriptions under one intake, making the switch straightforward.

Does Medicare cover compounded semaglutide during open enrollment? No. Medicare Part D covers only FDA-approved brand-name drugs. Compounded semaglutide and tirzepatide from 503A pharmacies are custom preparations and are not reimbursable by any Medicare plan. If you need GLP-1 on Medicare without qualifying CVD, cash pay is the primary option.

What if I miss open enrollment for GLP-1 coverage? If you miss your employer's open enrollment window, you generally cannot change coverage until next year unless you have a qualifying life event (job change, loss of other coverage, marriage, birth of a child). In the meantime, cash-pay compounded semaglutide from a licensed telehealth clinic has no enrollment window and is available year-round.

Is Zepbound covered during employer open enrollment? Zepbound (brand-name tirzepatide) is covered by many large commercial employer plans in 2026, subject to prior authorization. Medicare Part D does not cover Zepbound for weight loss (it covers Wegovy only, and only for CVD patients). For the full breakdown of Zepbound coverage by plan type, see our Zepbound insurance guide.

Top Picks | Related Reading

Clinic reviews:

• Wellorithm review
• HealthRX review
• Gala Health review

Related reading:

• Zepbound Insurance Coverage in 2026: Which Plans Pay?
• Medicare GLP-1 Bridge Program 2026: $50/Mo Wegovy & Zepbound
• GLP-1 Weight Loss Cost in 2026: All-In Prices Verified
• Semaglutide online: every clinic we track, priced
• Compounded vs Brand Semaglutide: Cost, Safety & How to Choose